journal article·2023-01Open access

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

Qin Liu, Yanhong Chu, Jie Shao, Hanqing Qian, Ju Yang, Huizi Sha, Lanqi Cen, Manman Tian, Qiuping Xu, Fangjun Chen, Yang Yang, Weifeng Wang, Kai Wang, Lixia Yu, Jia Wei, Baorui Liu

Advanced Science· Volume 10· Issue 1

Abstract

Abstract Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for adjuvant cancer immunotherapy is generated. PNVAC triggers superior protective efficacy against tumor recurrence and promotes longer survival than free neoantigens, especially when combined with anti‐PD‐1 treatment in a murine tumor model. A phase I clinical trial (ChiCTR1800017319) is initiated to evaluate the safety, immunogenicity, and prophylactic effect of PNVAC on preventing tumor recurrence in patients with high‐risk gastric/gastroesophageal junction cancer after adjuvant chemotherapy of postsurgical resection. The one‐ and two‐year disease‐free survival rates are significantly higher than historical record. PNVAC induces both CD4+ and CD8+ T cell responses as well as antigen‐experienced memory T cell phenotype. Furthermore, the immune response is persistent and remains evident one year after the vaccination. This work provides a safe and feasible strategy for developing neoantigen vaccines to delay gastric cancer recurrence after surgery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Comprehensive Cancer Centre of Drum Tower Hospital Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University Nanjing 210008 China

OrigiMed Shanghai 201114 China

Funding

National Natural Science Foundation of China

References (38)

Show source-provided references
1. 10.1126/science.aaa497110.1126/science.aaa4971 ↗
2. 10.1172/JCI9953810.1172/JCI99538 ↗
3. 10.1038/s41586-018-0810-y10.1038/s41586-018-0810-y ↗
4. 10.1038/s41586-018-0792-910.1038/s41586-018-0792-9 ↗
5. 10.1038/nature2299110.1038/nature22991 ↗
6. 10.1016/j.addr.2021.03.00110.1016/j.addr.2021.03.001 ↗
7. 10.1038/s41577-019-0269-610.1038/s41577-019-0269-6 ↗
8. 10.1002/adma.20120044610.1002/adma.201200446 ↗
9. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
10. 10.1016/S0140-6736(16)32226-710.1016/S0140-6736(16)32226-7 ↗
11. 10.1016/S1470-2045(21)00297-710.1016/S1470-2045(21)00297-7 ↗
12. 10.1186/s12885-021-07945-y10.1186/s12885-021-07945-y ↗
13. 10.1016/S1470-2045(14)70473-510.1016/S1470-2045(14)70473-5 ↗
14. 10.1002/cac2.1219310.1002/cac2.12193 ↗
15. 10.1158/1078-0432.CCR-19-288110.1158/1078-0432.CCR-19-2881 ↗
16. 10.1038/s41392-020-00448-510.1038/s41392-020-00448-5 ↗
17. Zeng Y. · J. Immunother. Cancer · 2020 · 8 · 1
18. 10.1080/21645515.2015.107145510.1080/21645515.2015.1071455 ↗
19. 10.1016/j.immuni.2019.12.01110.1016/j.immuni.2019.12.011 ↗
20. 10.1038/s41571-018-0142-810.1038/s41571-018-0142-8 ↗
21. 10.1126/scitranslmed.aan448810.1126/scitranslmed.aan4488 ↗
22. 10.21873/anticanres.1145110.21873/anticanres.11451 ↗
23. 10.1136/jitc-2021-00268810.1136/jitc-2021-002688 ↗
24. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
25. 10.1021/acs.chemrev.9b0047210.1021/acs.chemrev.9b00472 ↗
26. 10.1126/science.aar711210.1126/science.aar7112 ↗
27. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
28. 10.1126/scitranslmed.300806810.1126/scitranslmed.3008068 ↗
29. 10.1038/nrc166910.1038/nrc1669 ↗
30. 10.3390/vaccines906060610.3390/vaccines9060606 ↗
31. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
32. 10.1126/sciadv.aaw607110.1126/sciadv.aaw6071 ↗
33. 10.1021/jacs.7b1257910.1021/jacs.7b12579 ↗
34. 10.1073/pnas.200579411710.1073/pnas.2005794117 ↗
35. 10.1038/s41591-020-01206-410.1038/s41591-020-01206-4 ↗
36. 10.1016/j.annonc.2021.02.00410.1016/j.annonc.2021.02.004 ↗
37. 10.1158/1078-0432.CCR-20-208510.1158/1078-0432.CCR-20-2085 ↗
38. 10.1158/2159-8290.CD-21-021910.1158/2159-8290.CD-21-0219 ↗